| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HLA-DMB |
| Uniprot No | P28068 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-218aa |
| 氨基酸序列 | GGFVAHVESTCLLDDAGTPKDFTYCISFNKDLLTCWDPEENKMAPCEFGVLNSLANVLSQHLNQKDTLMQRLRNGLQNCATHTQPFWGSLTNRTRPPSVQVAKTTPFNTREPVMLACYVWGFYPAEVTITWRKNGKLVMPHSSAHKTAQPNGDWTYQTLSHLALTPSYGDTYTCVVEHIGAPEPILRDWTPGLSPMQTLK |
| 预测分子量 | 26.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HLA-DMB重组蛋白的模拟参考文献示例(请注意，以下内容为虚构，仅作格式参考)：
---
1. **文献名称**: "Structural and Functional Analysis of Recombinant HLA-DMB in Antigen Presentation"
**作者**: Smith, J.R., et al.
**摘要**: 本研究利用重组HLA-DMB蛋白解析其与MHC II类分子伴侣的相互作用，发现HLA-DMB通过调控抗原肽负载效率增强T细胞免疫应答，为自身免疫疾病机制提供新见解。
2. **文献名称**: "HLA-DMB Expression in Dendritic Cells: Role in Autoimmunity"
**作者**: Lee, H., & Tanaka, K.
**摘要**: 通过体外重组蛋白实验，证明HLA-DMB在树突状细胞中的表达缺失会导致MHC II类分子成熟障碍，与类风湿性关节炎患者中异常的自身抗原呈递密切相关。
3. **文献名称**: "Crystal Structure of HLA-DMB Reveals Key Binding Domains"
**作者**: Müller, F., et al.
**摘要**: 首次报道重组HLA-DMB蛋白的X射线晶体结构，揭示其α/β链构象及与HLA-DM相互作用的特异性位点，为靶向药物设计奠定结构基础。
4. **文献名称**: "Recombinant HLA-DMB as a Therapeutic Target in Cancer Immunotherapy"
**作者**: Chen, L., et al.
**摘要**: 实验表明，重组HLA-DMB蛋白可增强肿瘤细胞表面MHC II类分子的稳定性，提高CD4+ T细胞抗肿瘤活性，提示其在免疫检查点疗法中的潜在应用。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“HLA-DMB recombinant protein”或“HLA-DMB function”获取最新研究。
**Background of HLA-DMB Recombinant Protein**
HLA-DMB (Human Leukocyte Antigen class II DM beta chain) is a critical component of the HLA-DM heterodimer, a nonclassical MHC class II molecule essential for antigen presentation. Unlike classical MHC class II proteins, HLA-DM lacks direct antigen-binding capability but functions as a chaperone to facilitate peptide loading onto MHC class II molecules. HLA-DMB pairs with HLA-DMA to form HLA-DM, which stabilizes empty MHC II complexes and catalyzes the exchange of low-affinity peptides for high-affinity antigens in endosomal compartments. This process ensures the display of pathogen-derived or self-antigens on antigen-presenting cells (e.g., dendritic cells, B cells), enabling CD4+ T-cell activation and adaptive immune responses.
Recombinant HLA-DMB protein is engineered using expression systems (e.g., mammalian, insect cells) to produce soluble, functional forms for research. Its production often involves co-expression with HLA-DMA to mimic the native heterodimer. Studies leveraging recombinant HLA-DMB/DM proteins have elucidated mechanisms of immune regulation, including autoimmune disorders (e.g., lupus, rheumatoid arthritis) and infectious diseases, where dysregulated antigen presentation contributes to pathology. Additionally, HLA-DMB polymorphisms are linked to disease susceptibility, making it a focus for therapeutic targeting and vaccine design.
In drug discovery, recombinant HLA-DMB serves as a tool to screen molecules modulating antigen presentation or to develop inhibitors for autoimmune conditions. Its structural and functional characterization via X-ray crystallography and biochemical assays has advanced understanding of MHC II dynamics. Overall, HLA-DMB recombinant proteins are vital for dissecting immune pathways and developing immunotherapies.
(Word count: 249)
×
